PBAC's latest decision on Hydromorphone hydrochloride: Recommended (2018). Considered for Severe disabling pain. The submission requested PBS listing of a 200 mL oral liquid formulation as a replacement for the currently listed 473 mL glass bottle presentation.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
3
first 2005
Submissions
3
2005 → 2018
Eligible population
Patients with severe disabling pain unresponsive to non-opioid analgesics
Therapy area
Pain
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Economic model
BIA only
ICER note
Minor submission (formulation change only); no economic evaluation performed
Submission history
Jul 2005: Recommended with restriction · Restricted
Nov 2008: Recommended with restriction · Restricted